A Phase 1 Clinical Study of Intravenous Administration of PV701, an Oncolytic Virus, Using Two-Step Desensitization
Scott A. Laurie(Ottawa Hospital), Robert M. Lorence, John C. Bell(Ottawa Hospital), Michael K. Bamat(Wellstat Biologics (United States)), Joanne Roach, M. Scot Roberts(Altimmune (United States)), Harold Atkins(University of Ottawa), James D. O’Neil(Wellstat Biologics (United States)), William S. Groene(Wellstat Biologics (United States))
Cited by 128
Related Papers
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
|The Lancet Oncology|2008|522
American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer
|Journal of Clinical Oncology|2006|504